A master protocol to investigate a novel therapy acetyl-l-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia

Peer Review reports

Original Submission
27 Apr 2020	Submitted	Original manuscript
25 Sep 2020	Reviewed	Reviewer Report - Kirsty Loudon
1 Oct 2020	Reviewed	Reviewer Report - Marios Hadjivassiliou
18 Dec 2020	Author responded	Author comments - Taylor Fields
Resubmission - Version 2
18 Dec 2020	Submitted	Manuscript version 2
23 Dec 2020	Reviewed	Reviewer Report - Kirsty Loudon
23 Dec 2020	Reviewed	Reviewer Report - Marios Hadjivassiliou
Resubmission - Version 3
	Submitted	Manuscript version 3
Publishing
28 Dec 2020	Editorially accepted
22 Jan 2021	Article published	10.1186/s13063-020-05009-3

Back to article page